ArticleCureus2025
A Case of Ertapenem-Induced Neurotoxicity in an Elderly Patient With Reduced Renal Function.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ertapenem-induced neurotoxicity is a rare, often underreported side effect, primarily seen in elderly patients with impaired renal function. We report the case of an 87-year-old woman with a history of chronic kidney disease (CKD) and bilateral hydronephrosis, who presented with acute neurological symptoms, including left-sided weakness and slurred speech. Prior to this presentation, she had been treated for a left-sided nephrostomy site infection and left-sided perinephric collection with intravenous ertapenem at an ambulatory emergency care (AEC) center. An initial computed tomography (CT) scan of the brain showed no acute changes, but we treated her for a possible stroke while awaiting a magnetic resonance imaging (MRI) scan of the brain and continued intravenous ertapenem for the associated urological infection. However, the patient's condition continued to deteriorate, with the onset of further neurological symptoms, such as left-sided sensory deficits and constant myoclonic movements. An MRI scan of the brain showed no significant changes. The patient was diagnosed with ertapenem-induced neurotoxicity. We discontinued the antibiotic and switched to meropenem. Her neurological symptoms gradually improved and subsided within a week of stopping ertapenem. This case highlights the importance of clinical suspicion of ertapenem-induced neurotoxicity in elderly and frail patients with reduced renal function who present with unexplained neurological symptoms. Prompt recognition of the condition facilitates accurate diagnosis and management. Treatment is simple and involves discontinuing the offending drug, leading to favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.